3 not yet recruiting, 3 recruiting, 2 completed, 1 active not recruiting. 5 Phase 3, 3 Phase 2, 1 Phase 1.
By phase and status
Follow Enicepatide: new trials by email Literature Review of Enicepatide trials Research Report on Enicepatide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease Enicepatide, Placebo - Overweight, Obesity Phase 3 Not yet recruiting 8200 2027-01-06 2026-11-05
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications Enicepatide, Tirzepatide - Type 2 Diabetes Mellitus Phase 3 Not yet recruiting 948 2026-12-01 2026-10-22
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight Petrelintide, Enicepatide, Petrelintide-matching Placebo - Obesity or Overweight Phase 2 Not yet recruiting 486 2026-11-30 2026-11-03
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes Enicepatide, Placebo - Obesity, Overweight Phase 3 Recruiting 300 2026-07-03 2026-11-05
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants Enicepatide, Placebo - Healthy Participants Phase 1 Active not recruiting 36 2026-07-02 2026-11-05
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes Placebo, Enicepatide - Obesity or Overweight, Type 2 Diabetes Mellitus Phase 3 Recruiting 1600 2026-03-23 2026-11-09
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes Placebo, Enicepatide - Obesity or Overweight Phase 3 Recruiting 2000 2026-03-16 2026-11-09
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus Placebo, Enicepatide - Overweight or Obese, Type 2 Diabetes Mellitus (T2DM) Phase 2 Completed 447 2024-11-21 2026-10-28
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Placebo, Enicepatide - Obesity, Overweight Phase 2 Completed 469 2024-08-16 2026-10-05
Conditions studied Obesity (7) · Overweight (7) · Diabetes Mellitus, Type 2 (4) · Cardiovascular Diseases (1)
Sponsors Hoffmann-La Roche (7) · Carmot Therapeutics, Inc. (2)
Countries China (4) · United States (4) · Argentina (3) · Canada (3) · Mexico (3) · Australia (2) · Brazil (2) · Czechia (2) · France (2) · Germany (2) · India (2) · Italy (2) · Japan (2) · Poland (2) · Puerto Rico (2)
NIH funding 2025 (2)